Search

Blog

We constantly analyse the legislation and regulatory information related to a specific medicine in order to appraise the context in which the company operates

We put all our knowledge into play to anticipate risks and seize every opportunity, but above all to understand the rules of the game and display our creativity with them. We spread material and information proceeding from our investigation into medicines governance and regulatory science. In fact, we deem it necessary to be aware of the complexity of the results of research, regulation and drug policy in order to be able to work in a cultural ecosystem aiming both at promoting research outcomes that are useful to patients and at encouraging politicians to protect people’s health. The wider the knowledge of each interest group, the greater their ability to interact and achieve transparency of procedures and health protection.

  • All
  • Scenario analysis
  • Notes
  • Drug Policy
  • Rare Diseases
  • Mapping
  • Team Pharma Value
All
  • All
  • Scenario analysis
  • Notes
  • Drug Policy
  • Rare Diseases
  • Mapping
  • Team Pharma Value
Training for Astrazeneca

A unique cross-functional training experience with AstraZeneca

On 28 November 2024, Pharma Value partnered with AstraZeneca to organise an in-house training day of great innovative value. A ...
Read more "

Pharma Value at the 10th National Congress ISPOR Italy - Rome Chapter

On 4-5 December 2024, Pharma Value participated in the 10th National Congress ISPOR Italy - Rome Chapter with two scientific contributions, ...
Read more "

Pharma Value at ISPOR Europe 2024

The Pharma Value team participated in ISPOR Europe 2024, held in Barcelona from 17 to 20 November. Under the theme 'Generating Evidence ...
Read more "

Budget Law 2025: possible changes to the innovativeness criteria

Aggiornamento 20 dicembre 2024 Il 28 dicembre 2024, il Senato della Repubblica ha approvato in via definitiva la Legge di Bilancio per ...
Read more "

8th Orphan Drug Day - The Orphan Drug Comparator - Limits and the right to the best treatment

Rome, 16 October 2024 - In the context of rare diseases, orphan drugs play a key role because they treat conditions for which there are ...
Read more "

AIFA administrative sanctions

Clarification of AIFA Administrative Sanctions The law recognises that AIFA - as the drug regulatory authority - has the power to impose administrative sanctions ...
Read more "
Special HTA Regulation

Pharma Value Special: The new HTA Regulation

Special European HTA Regulation The new European Regulation on Health Technology Assessment (HTA-r) 2021/2282, which comes into force on 12 January 2025, marks the ...
Read more "
GIRF Bologna

Pharma Value at the 3rd GIRF Congress - ISPOR Group Rome for Future

On 19 and 20 June, the 3rd National Congress of the Ispor Roma for Future GIRF group was held in Bologna, confirming ...
Read more "
Aifa Guidelines - Pharma Value comments

Technical Table for the revision of AIFA Notes and Therapeutic Plans

Update 17 June 2024 Below are the appointments updated to 17 June 2024. On the AIFA website you can read the new determination ...
Read more "
en_GB